Docking, virtual high throughput screening and in silico fragment-based drug design |
| |
Authors: | Vincent Zoete,Auré lien Grosdidier,Olivier Michielin |
| |
Affiliation: | Swiss Institute of Bioinformatics, Molecular Modeling Group, Bâtiment Génopode, Quartier Sorge, Lausanne, Switzerland;Ludwig Institute for Cancer Research, Lausanne Branch, Ch. Des Boveresses, Epalinges, Switzerland;Multidisciplinary Oncology Center (CePO), Rue du Bugnon, Lausanne, Switzerland |
| |
Abstract: | The drug discovery process has been profoundly changed recently by the adoption of computational methods helping the design of new drug candidates more rapidly and at lower costs. In silico drug design consists of a collection of tools helping to make rational decisions at the different steps of the drug discovery process, such as the identification of a biomolecular target of therapeutical interest, the selection or the design of new lead compounds and their modification to obtain better affinities, as well as pharmacokinetic and pharmacodynamic properties. Among the different tools available, a particular emphasis is placed in this review on molecular docking, virtual high-throughput screening and fragment-based ligand design. |
| |
Keywords: | docking virtual high-throughput screening fragment-based drug design |
|
|